Fox Run Management’s Regenxbio RGNX Stock Holding History

Fox Run Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,501	Closed	-$252K	–	1188
2025 Q4	$252K	Buy	+17,501	New	+$218K	0.04%	742
2025 Q1	–	Sell	-13,784	Closed	-$107K	–	1172
2024 Q4	$107K	Sell	13,784 -656	-5%	-$6.16K	0.02%	802
2024 Q3	$151K	Buy	+14,440	New	+$176K	0.03%	702
2019 Q3	–	Sell	-5,240	Closed	-$269K	–	528
2019 Q2	$269K	Buy	+5,240	New	+$262K	0.18%	269
2019 Q1	–	Sell	-10,975	Closed	-$460K	–	653
2018 Q4	$460K	Buy	+10,975	New	+$644K	0.24%	133

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's RGNX Position: Q1 2026 in Review

Fox Run Management sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 17,501 shares — an estimated $252K sold.

Fox Run Management first reported a position in RGNX in Q4 2018 and held it in 5 quarters. The position peaked at $460K in Q4 2018. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Fox Run Management reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 17,501 Regenxbio shares in Q1 2026, an estimated $252K.
Fox Run Management first reported a position in Regenxbio in Q4 2018 and held it in 5 quarters.
Fox Run Management's Regenxbio position peaked at $460K in Q4 2018.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.